Compare iShares MSCI Taiwan ETF (EWT) vs Travere Therapeutics Inc. Common Stock (TVTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares MSCI Taiwan ETF vs Travere Therapeutics Inc. Common Stock — how do they compare? iShares MSCI Taiwan ETF trades at $107.53 (market cap $12.49B), while Travere Therapeutics Inc. Common Stock trades at $52.74 (market cap $4.88B). The key difference: iShares MSCI Taiwan ETF is far larger — about 2.6× Travere Therapeutics Inc. Common Stock's market cap, and iShares MSCI Taiwan ETF is trading nearer its 52-week high, Travere Therapeutics Inc. Common Stock nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold iShares MSCI Taiwan ETF for 53 Days and Travere Therapeutics Inc. Common Stock for 0 Days on average.
| EWT | TVTX | |
|---|---|---|
Market Cap | $12.49B | $4.88B |
Volume | 5,965,495 | 1,668,577 |
Sector | Broad Market / Factor | Health |
52-Week High | $118.00 | $67.52 |
52-Week Low | $60.03 | $26.79 |
Typical Hold Time | 53 Days | 0 Days |
Enterprise Value | — | $5.01B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
EWT (iShares MSCI Taiwan ETF) trades at $113.46, down 0.71% on the day, with technical indicators showing a bullish trend from moving averages while oscillators remain neutral. The ETF maintains strong exposure to Taiwan's semiconductor sector, particularly TSMC, which represents 22.5% of holdings. Recent news highlights Taiwan's strategic position in AI chip manufacturing with companies planning $20 billion in US investments.
The ETF offers exposure to Taiwan's dominant semiconductor industry but faces significant geopolitical risks. Strong AI-driven fundamentals and reasonable tech valuations support upside potential, though China-Taiwan tensions represent a persistent overhang. Institutional interest remains positive with Bank of America increasing its stake by 22.4% in the latest quarter.
Travere Therapeutics (TVTX) trades at $51.80, down 0.42% on the day, with a neutral technical signal. The company reported strong revenue growth but persistent net losses, with a 2025 net income margin of -7.35%. Recent news includes new data presentations for its key drug FILSPARI and a CEO transition. Analyst consensus is strongly bullish with an 83.33% buy rating and a $70.60 price target, suggesting significant upside from the current price.
The outlook for TVTX hinges on the commercial success of FILSPARI, which shows promising sales growth, but profitability remains a challenge. Key risks include execution of the CEO transition, competitive pressures in nephrology treatments, and the company's ability to achieve sustained profitability. The high valuation multiples relative to negative earnings present a risk-reward balance for investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About iShares MSCI Taiwan ETF
EWT tracks the MSCI Taiwan 25/50 Index, providing targeted exposure to large and mid-cap companies in Taiwan. It is heavily concentrated in the information technology sector, serving as a liquid instrument for investors seeking a single-country view of Taiwan's export-oriented and tech-driven economy.
Read more on EWT →About Travere Therapeutics Inc. Common Stock
Travere Therapeutics Inc. is a biopharmaceutical company focused on rare kidney and metabolic diseases. Its lead product, FILSPARI (sparsentan), is an oral medication for adults with IgA nephropathy, and it also markets Thiola for cystinuria.
Read more on TVTX →
